Table 7– Odds of treatment outcomes by extensively drug-resistant tuberculosis (XDR-TB) patient group
XDR aloneXDR+2sliXDR+sliG4XDR+sliG4EZ
Subjects301684842
Univariable random effects logistic regression (pooled unadjusted odds)
 Treatment success1.0 (ref.)0.4 (0.2–0.8)0.6 (0.2–1.6)0.6 (0.2–1.8)
 Treatment failure1.0 (ref.)1.8 (0.7–4.5)1.5 (0.6–3.7)1.5 (0.6–3.9)
 Death1.0 (ref.)1.8 (0.7–4.7)1.6 (0.6–4.5)1.7 (0.6–4.8)
 Treatment failure or death1.0 (ref.)2.4 (1.2–4.8)2.2 (1.0–5.1)2.4 (1.0–5.9)
 Defaulted1.0 (ref.)1.0 (0.4–2.6)0.6 (0.2–1.7)0.5 (0.2–1.8)
Multivariable random effects logistic regression (pooled adjusted odds#)
 Treatment success1.0 (ref.)0.4 (0.2–0.8)0.6 (0.2–1.6)0.5 (0.2–1.7)
 Treatment failure1.0 (ref.)2.1 (1.0–4.5)1.8 (0.7–4.7)1.9 (0.7–5.3)
 Death1.0 (ref.)1.6 (0.6–4.4)1.7 (0.6–4.9)1.8 (0.6–5.3)
 Treatment failure or death1.0 (ref.)2.6 (1.2–4.4)2.6 (1.1–6.7)2.8 (1.0–7.9)
 Defaulted1.0 (ref.)1.0 (0.3–2.6)0.5 (0.2–1.8)0.5 (0.1–2.0)
  • Data are presented as n or OR (95% CI). Statistically significant results are presented in bold type. XDR alone: resistance to isoniazid and rifampicin, plus any fluoroquinolone and any second-line injectable drug (sli); XDR+2sli: XDR-TB, plus resistance to both an aminoglycoside injectable (kanamycin/amikacin) and to capreomycin; XDR+sliG4: XDR-TB, plus resistance to all second-line TB drugs tested, with, as a minimum, resistance to kanamycin and to at least one group 4 drug (G4); XDR+sliG4EZ: XDR-TB, plus resistance to all first- and second-line TB drugs tested, with, as a minimum, resistance to kanamycin, one group 4 drug and either pyrazinamide (Z) and/or ethambutol (E); ref.: reference. #: adjusted for age, sex, HIV co-infection, severity of disease and previous treatment episodes with first- or second-line TB drugs.